44 related articles for article (PubMed ID: 33485459)
1. Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries.
Soerjomataram I; Cabasag C; Bardot A; Fidler-Benaoudia MM; Miranda-Filho A; Ferlay J; Parkin DM; Ranganathan R; Piñeros M; Znaor A; Mery L; Joko-Fru YW; Dikshit R; Sankaranarayanan R; Swaminathan R; Bray F;
Lancet Oncol; 2023 Jan; 24(1):22-32. PubMed ID: 36603919
[TBL] [Abstract][Full Text] [Related]
2. Comparison of liver cancer incidence and survival by subtypes across seven high-income countries.
Rutherford MJ; Arnold M; Bardot A; Ferlay J; De P; Tervonen H; Little A; Bucher O; St Jacques N; Gavin A; Engholm G; Møller B; O'Connell DL; Merrett N; Parkin DM; Bray F; Soerjomataram I
Int J Cancer; 2021 Dec; 149(12):2020-2031. PubMed ID: 34460109
[TBL] [Abstract][Full Text] [Related]
3. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study.
Wilson BE; Jacob S; Yap ML; Ferlay J; Bray F; Barton MB
Lancet Oncol; 2019 Jun; 20(6):769-780. PubMed ID: 31078462
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study.
Cabasag CJ; Arnold M; Rutherford M; Bardot A; Ferlay J; Morgan E; Little A; De P; Dixon E; Woods RR; Saint-Jacques N; Evans S; Engholm G; Elwood M; Merrett N; Ransom D; O'Connell DL; Bray F; Soerjomataram I
Br J Cancer; 2022 Jun; 126(12):1774-1782. PubMed ID: 35236937
[TBL] [Abstract][Full Text] [Related]
5. The impact of the COVID-19 pandemic on radiotherapy services in England, UK: a population-based study.
Spencer K; Jones CM; Girdler R; Roe C; Sharpe M; Lawton S; Miller L; Lewis P; Evans M; Sebag-Montefiore D; Roques T; Smittenaar R; Morris E
Lancet Oncol; 2021 Mar; 22(3):309-320. PubMed ID: 33493433
[TBL] [Abstract][Full Text] [Related]
6. Aligning Cancer Clinical Trials With Cancer Burden: Need for Greater Global Leadership, Resources, and Vision.
Desai A; Kuderer NM; Lyman GH
JAMA Oncol; 2021 Mar; 7(3):357-358. PubMed ID: 33507227
[No Abstract] [Full Text] [Related]
7. Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline.
Daly ME; Ismaila N; Decker RH; Higgins K; Owen D; Saxena A; Franklin GE; Donaldson D; Schneider BJ
J Clin Oncol; 2021 Mar; 39(8):931-939. PubMed ID: 33502911
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral heterogeneity in cancer progression and response to immunotherapy.
Vitale I; Shema E; Loi S; Galluzzi L
Nat Med; 2021 Feb; 27(2):212-224. PubMed ID: 33574607
[TBL] [Abstract][Full Text] [Related]
9. Unlocking the Power of Benchmarking: Real-World-Time Data Analysis for Enhanced Sarcoma Patient Outcomes.
Fuchs B; Schelling G; Elyes M; Studer G; Bode-Lesniewska B; Scaglioni MF; Giovanoli P; Heesen P; On Behalf Of The SwissSarcomaNetwork
Cancers (Basel); 2023 Sep; 15(17):. PubMed ID: 37686671
[TBL] [Abstract][Full Text] [Related]
10. Do Lipid-based Nanoparticles Hold Promise for Advancing the Clinical Translation of Anticancer Alkaloids?
Loh JS; Tan LKS; Lee WL; Ming LC; How CW; Foo JB; Kifli N; Goh BH; Ong YS
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771511
[TBL] [Abstract][Full Text] [Related]
11. Global demand for cancer surgery and an estimate of the optimal surgical and anaesthesia workforce between 2018 and 2040: a population-based modelling study.
Perera SK; Jacob S; Wilson BE; Ferlay J; Bray F; Sullivan R; Barton M
Lancet Oncol; 2021 Feb; 22(2):182-189. PubMed ID: 33485458
[TBL] [Abstract][Full Text] [Related]
12. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study.
Arnold M; Rutherford MJ; Bardot A; Ferlay J; Andersson TM; Myklebust TÅ; Tervonen H; Thursfield V; Ransom D; Shack L; Woods RR; Turner D; Leonfellner S; Ryan S; Saint-Jacques N; De P; McClure C; Ramanakumar AV; Stuart-Panko H; Engholm G; Walsh PM; Jackson C; Vernon S; Morgan E; Gavin A; Morrison DS; Huws DW; Porter G; Butler J; Bryant H; Currow DC; Hiom S; Parkin DM; Sasieni P; Lambert PC; Møller B; Soerjomataram I; Bray F
Lancet Oncol; 2019 Nov; 20(11):1493-1505. PubMed ID: 31521509
[TBL] [Abstract][Full Text] [Related]
13. Estimation of an optimal chemotherapy utilisation rate for cancer: setting an evidence-based benchmark for quality cancer care.
Jacob SA; Ng WL; Do V
Clin Oncol (R Coll Radiol); 2015 Feb; 27(2):77-82. PubMed ID: 25455844
[TBL] [Abstract][Full Text] [Related]
14. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based benchmarks for use of cancer surgery in high-income countries: a population-based analysis.
Perera SK; Jacob S; Sullivan R; Barton M
Lancet Oncol; 2021 Feb; 22(2):173-181. PubMed ID: 33485459
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
